dapirolizumab pegol

News

EULAR 26 hears of treatment advances in lupus

Three trials of potentially first-in-class therapies for J&J, UCB/Biogen, and Merck KGaA at EULAR have offered hope of new targeted drugs for lupus.

News

Person holds their hand, radiating pain from the palm.

Data at EULAR back Biogen, UCB's first-in-class lupus drug

Hopes rise for a new treatment option for people living with lupus, after UCB and Biogen reveal phase 3 data with their anti-CD40L antibody DZP.

News

football going into the net past goalkeeper to score

UCB, Biogen lupus drug scores in phase 3 trial

UCB and Biogen say their first phase 3 trial of their systemic lupus erythematosus (SLE) candidate dapirolizumab pegol was a success, and a second is now expected to start before the end of

EULAR 26 hears of treatment advances in lupus

Data at EULAR back Biogen, UCB's first-in-class lupus drug

UCB, Biogen lupus drug scores in phase 3 trial

FDA cites 'significant concerns' with ADC lymphoma trial

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks